List of Oleptro drug patents

Oleptro is owned by Angelini Pharma.

Oleptro contains Trazodone Hydrochloride.

Oleptro has a total of 2 drug patents out of which 0 drug patents have expired.

Oleptro was authorised for market use on 02 February, 2010.

Oleptro is available in tablet, extended release;oral dosage forms.

Oleptro can be used as method of treating depression.

The generics of Oleptro are possible to be released after 13 March, 2029.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8133893 ANGELINI PHARMA Trazodone and trazodone hydrochloride in purified form
Mar, 2029

(6 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7829120 ANGELINI PHARMA Trazodone composition for once a day administration
Mar, 2027

(4 years from now)

Drugs and Companies using TRAZODONE HYDROCHLORIDE ingredient

Market Authorisation Date: 02 February, 2010

Treatment: Method of treating depression

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of OLEPTRO before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic